## NOVA PHARMA SOLUTIONS BERHAD

(Company No. 34608 K)
SUMMARY OF KEY FINANCIAL INFORMATION FOR THE HALF YEAR ENDED 30 JUNE 2019

|  |  | UNAUDITED INDIVIDUAL <br> 6 months ended 30 June |  | UNAUDITED CUMULATIVE <br> 6 months ended 30 June |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $\underline{2019}$ | 2018 | $\underline{2019}$ | $\underline{2018}$ |
|  |  | RM'000 | RM'000 | RM'000 | $\underline{\text { RM'000 }}$ |
| 1 | Revenue | 3,172 | 2,869 | 3,172 | 2,869 |
| 2 | Profit before tax | 691 | 546 | 691 | 546 |
| 3 | Profit for the period | 690 | 540 | 690 | 540 |
| 4 | Profit and total comprehensive income attributable to owners of the Company | 690 | 540 | 690 | 540 |
| 5 | Basic earnings per share (Subunit-sen) | 0.46 | 0.37 | 0.46 | 0.37 |
| 6 | Proposed/Declared dividend per share (Subunit-sen) | - | - | - |  |
|  |  | Unaudited as at 30 June 2019 |  | Unaudited as at 31 December 2018 |  |
| 7 | Net assets per share (RM) attributable to ordinary equity holders of the company | 0.07 |  | 0.07 |  |

Note 1: Basic earnings per share for the current period is computed based on profit for the period divided by weighted average number of shares which are detailed in Note C5 of this interim financial report.
Note 2: Proposed/Declared dividend per share is computed based on total dividend declared divided by weighted average number of shares which are detailed in Note C5 of this interim financial report.

|  |  | INDIVIDUAL <br> half year ended 30 June |  | CUMULATIVE <br> 6 months ended 30 June |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $\underline{2019}$ | 2018 | $\underline{2019}$ | $\underline{2018}$ |
|  |  | RM'000 | RM'000 | RM'000 | RM'000 |
| 1 | Gross interest income | 3 | 26 | 3 | 26 |
| 2 | Gross interest expense | - | - | - | - |

